ClinicalTrials.gg

Program

linsitinib

Also written as “OSI-906” and “Linsitinib”.

Its studies are mostly in Graves Ophthalmopathy · Carcinoma, Non-Small-Cell Lung · Ovarian Neoplasms · Adrenocortical Carcinoma · Carcinoma, Hepatocellular, led by 2 companies.

Furthest: phase 3, since Jun 17, 200913 company-led studies, 2 open or runningNext primary completion: Jun 30, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Astellas Pharma100 open or runningphase 3since Jun 17, 2009Aug 7, 2007none ahead
Sling Therapeutics32 open or runningphase 3since Mar 2, 2022Mar 2, 2022Jun 30, 2028phase 3 · NCT07753603

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 7, 2007First studies: 2 phase 1 studiesNew to Astellas PharmaAstellas Pharma · NCT00514306, NCT00514007
  2. Aug 19, 2008Phase 1 study in Pancreatic NeoplasmsAstellas Pharma · NCT00739453 · 95 enrolled · United States, United Kingdom
  3. Apr 6, 2009Phase 2 study in Ovarian NeoplasmsAstellas Pharma · NCT00889382 · 152 enrolled · United States, Australia, Canada and more
  4. Jun 17, 2009Phase 3 study in Adrenocortical CarcinomaAstellas Pharma · NCT00924989 · 139 enrolled · United States, Australia, Canada and more
  5. Apr 8, 2010Phase 2 study in Carcinoma, HepatocellularAstellas Pharma · NCT01101906 · 23 enrolled · United States, Belgium, France and more
  6. Aug 19, 2010Phase 2 study in Carcinoma, Non-Small-Cell LungAstellas Pharma · NCT01186861 · 205 enrolled · United States, Brazil, Canada and more
  7. Oct 5, 2010Phase 2 study in Carcinoma, Non-Small-Cell LungAstellas Pharma · NCT01221077 · 88 enrolled · United States, Canada, Hong Kong and more
  8. Feb 7, 2012Phase 1 study in NeoplasmsAstellas Pharma · NCT01529684 · 5 enrolled · United States
  9. Feb 5, 2014Phase 2 study in Advanced Solid TumorsAstellas Pharma · NCT02057380 · 13 enrolled · United States, Brazil, Czechia and more
  10. Mar 2, 2022Sling Therapeutics's first study: phase 3 study in Graves OphthalmopathyNew to Sling TherapeuticsSling Therapeutics · NCT05276063 · 90 enrolled · United States, Canada, Italy and more
  11. Oct 16, 2023Phase 3 study in Graves OphthalmopathySling Therapeutics · NCT06112340 · 75 planned · United States
  12. Aug 3, 2026Phase 3 study in Graves OphthalmopathySling Therapeutics · NCT07753603 · 130 planned · United States

Ahead

  1. Jun 30, 2028Primary completion: phase 3 study in Graves OphthalmopathySling Therapeutics · NCT07753603

TargetBeta

IGF1R →INSR →read by rule
“An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) ”NCIt, by rule
“Insulin-like growth factor I receptor inhibitor; Insulin receptor inhibitor”ChEMBL 37, by rule

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07753603Graves Ophthalmopathy · United States3RecruitingSling TherapeuticsJun 30, 2028130
NCT06112340Graves Ophthalmopathy · United States3RecruitingSling TherapeuticsJun 202675
NCT05276063Graves Ophthalmopathy · United States, Canada, Italy and more3CompletedSling TherapeuticsOct 15, 202490
NCT02057380Advanced Solid Tumors · United States, Brazil, Czechia and more2CompletedAstellas PharmaOct 14, 201613
NCT01529684Neoplasms · United States1CompletedAstellas PharmaDec 8, 20125
NCT01221077Carcinoma, Non-Small-Cell Lung · United States, Canada, Hong Kong and more2CompletedAstellas PharmaMar 1, 201388
NCT01186861Carcinoma, Non-Small-Cell Lung · United States, Brazil, Canada and more2CompletedAstellas PharmaJul 1, 2013205
NCT01101906Carcinoma, Hepatocellular · United States, Belgium, France and more2TerminatedAstellas PharmaNov 4, 201123
NCT00924989Adrenocortical Carcinoma · United States, Australia, Canada and more3CompletedAstellas PharmaJul 11, 2012139
NCT00889382Ovarian Neoplasms · United States, Australia, Canada and more2CompletedAstellas PharmaAug 1, 2014152
NCT00739453Pancreatic Neoplasms · United States, United Kingdom1CompletedAstellas PharmaMar 3, 201295
NCT00514306Ovarian Neoplasms · United States, United Kingdom1CompletedAstellas PharmaSep 20, 201079
NCT00514007Colorectal Neoplasms · United States, United Kingdom1CompletedAstellas PharmaMar 19, 201295

How it is read

Names in the registry

  • “OSI-906”, 9 entries
  • “linsitinib”, 3 entries
  • “Linsitinib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.